

AMS WEEKLY EQUITY REPORT

PHARM Weekly Report

Pharming Group N.V.

PHARM closed the latest completed week at 1.10 EUR. The 4-week return is -5.3% and the 12-week return is -22.9%. The trend backdrop is inactive, with activity pressure at -0.98.

Field	Value	Field	Value
Week ending	24 Jul 2026	Evidence rating	Caution
Evidence score	33	Currency	EUR
Exchange	AMS	Country	NL
Sector	Healthcare	Industry	Biotechnology
Market cap	793.5M	Report page	Available online

OPEN 1.15 EUR weekly open	HIGH 1.16 EUR weekly high	LOW 1.10 EUR weekly low	CLOSE 1.10 EUR weekly close	VOLUME 23.9M latest week	TREND 69.2% 36 of 52 weeks active
---	---	---	---	--	---

Company brief

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent...

EXECUTIVE READ

What matters now

Top-level conclusion, primary support, and the main restraint in the current weekly setup.

Conclusion

The strongest supporting evidence is sentiment: Weighted news tone is positive across 1 relevant articles. The main constraint is indicator analysis: Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12. The combined read is defensive, so risk control and evidence of stabilization matter more than headline upside.


Read	Pillar	Score	Detail
Primary support	Sentiment	66/100	Weighted news tone is positive across 1 relevant articles.
Main restraint	Indicator analysis	9/100	Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

WEEKLY TAPE

Price, Trend Line, and Fair Value

Price path, range position, trend distance, Fair Value gap, and return windows.

52-week price path



Black: weekly close. Green: Trend Line. Grey: Fair Value.

TREND DISTANCE -17.0% price vs Trend Line	FAIR GAP 5.8% price vs Fair Value	DRAWDOWN -39.3% from 52-week high	RANGE 26.6% 52-week range	VOLUME 0.6x vs 13-week average
---	---	---	---	--


Pillar	Score	Read	Detail
1W	-3.7%	Negative	
4W	-5.3%	Negative	
12W	-22.9%	Negative	
26W	-34.0%	Negative	
52W	28.2%	Positive	

SETUP

Composite setup scorecard

Current setup pillars scored on the same 0-100 scale.

Composite radar



Pillar	Score	Read	Detail
Trend	38	Neutral	
Momentum	17	Negative	
Activity Pressure	35	Neutral	
Relative Leadership	0	Negative	
Next-Week Expectancy	50	Neutral	
Volume	25	Negative	
Smart Money	32	Negative	
Risk Control	0	Negative	

Current evidence clusters


Pillar	Score	Read	Detail
Price follow-through	-3.7%	Negative	Latest completed week; four-week move -5.3%.
Indicator stack	38/35	Negative	Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop	Active	Positive	The trend backdrop defines the current weekly regime.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment	66/100	Positive	1 relevant articles in the latest sentiment read.

INDICATOR EVIDENCE

Activity pressure, trend confirmation, and next-week expectancy


The current 12-week confirmation window, activity-pressure read, and historical one-week setup read.

Activity pressure path



Latest 0.04 | 12-week average 0.22

Next-week expectancy path



Current Undecided 51.67% historical one-week setup read

Pillar	Score	Read	Detail
Trend active	0/12	Negative	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	0/12	Negative	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	0/12	Negative	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.04	Negative	Current proprietary activity-pressure read.
Buy signals	0	Neutral	Accumulation signal count in the latest 12 weeks.
Reversal markers	0	Positive	No reversal markers

Area	Latest read	Detail
Activity pressure	-0.98	Four-week pressure change 33.4%.
Relative leadership	-23.72	Four-week relative leadership change -43.1%.
Smart money activity	50	No recent accumulation markers. No reversal markers.

PARTICIPATION AND RISK

Volume, volatility, and return shape

Participation confirms attention; return shape frames the current risk profile.

Area	Latest	Baseline	Read
Volume	23.9M	13W 40.2M 52W 67.2M	0.6x vs 13-week average
Volatility	6.7%	52W 7.8%	29 upside weeks / 23 downside weeks
Average move	5.5%	-5.2%	Downside breadth 44.2%

Pillar	Score	Read	Detail
Participation	0.6x	Neutral	Latest volume versus the 13-week average.
Baseline	40.2M	Neutral	13-week average volume.
One-year base	67.2M	Neutral	52-week average volume.
Recent vol	6.7%	Neutral	13-week weekly-return volatility.
Base vol	7.8%	Neutral	52-week weekly-return volatility.
Up/down split	29/23	Positive	Count of positive and negative weeks in the 52-week window.
Average skew	5.5% / -5.2%	Neutral	Average positive week versus average negative week.

EXTERNAL CONFIRMATION

Options, sentiment, events, insiders, and research flow

Supporting evidence that can confirm, challenge, or qualify the weekly tape.

Pillar	Score	Read	Detail
Weekly tape	27/100	Negative	Trend, activity pressure, participation, and risk combine to a 27/100 tape read.
Indicator analysis	9/100	Negative	Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Factors	50/100	Neutral	No published factor snapshot is available yet.
Patient Capital	Quiet	Neutral	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Sentiment	66/100	Positive	Weighted news tone is positive across 1 relevant articles.
Insiders	50/100	Neutral	No recent insider transaction evidence is stored.
Earnings	50/100	Neutral	No stored earnings event is currently attached to this ticker.

Evidence	Current read	Detail
Sentiment	66/100	1 relevant articles. Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case

SECTOR CONTEXT

Sector and industry pulse

Group context helps separate stock-specific movement from broader rotation.

Group	Scope	Peers	4W rank	Trend breadth
Sector	NL Healthcare	3	3 of 3	0.0%
Industry	NL Biotechnology	2	2 of 2	0.0%

Sector leaders

Peer	Exchange	1W	4W	Trend
VVY	AMS	1.3%	8.8%	Off
PHIA	AMS	-1.9%	-2.8%	Off
PHARM	AMS	-3.7%	-5.3%	Off

Industry leaders

Peer	Exchange	1W	4W	Trend
VVY	AMS	1.3%	8.8%	Off
PHARM	AMS	-3.7%	-5.3%	Off

ACTIONABLE READ

Opportunities, risks, and watch points

Evidence clusters to monitor as the next weekly bar develops.

Opportunity signals

- Price is above Fair Value, showing premium demand versus the model.
- Latest weekly return ranks in the strongest part of its sector group.

Risk signals

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.

Watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

EVIDENCE TRAIL

Recent completed weeks

Recent weekly bars behind the report.

Week	Close	Move	Trend	Activity	Volume
24 Jul	1.10 EUR	-3.7%	Off	-0.98	23.9M
17 Jul	1.15 EUR	-4.7%	Off	-1.00	31.1M
10 Jul	1.20 EUR	-2.1%	Off	-1.07	43.5M
03 Jul	1.23 EUR	5.3%	Off	-1.27	42.0M
26 Jun	1.17 EUR	3.2%	Off	-1.48	42.6M
19 Jun	1.13 EUR	1.4%	Off	-1.55	4.3M
12 Jun	1.11 EUR	-0.3%	Off	-1.63	5.9M
05 Jun	1.12 EUR	-3.0%	Off	-1.66	18.2M
29 May	1.15 EUR	3.0%	Off	-1.58	64.0M
22 May	1.12 EUR	0.8%	Off	-1.44	31.0M

Report footer

Copyright 2026 Sharemaestro. All rights reserved.

sharemaestro.com | [Open this report online](#) | [Full disclaimer](#)

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.